Conjunctival transposition surgery for primary pterygium
Official title: Conjunctival Transpositional Pterygium Surgery: A Prospective Single-Arm Interventional Study
Run by Zahedan University of Medical Sciences · NCT07343011 · Data updated 2026-11-12
This surgery tries moving and repositioning your own pterygium tissue during the operation to see if it lowers regrowth and keeps the eye surface healthy in adults with primary pterygium.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Zahedan University of Medical Sciences Academic / other |
| Locations | 1 site (Zahedan, Sistan and Balochistan) |
| Status | Recruiting |
| Started | May 21, 2025 |
| Main results expected | May 1, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT07343011 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 years or older with a primary pterygium that involves the cornea and who can provide informed consent are ideal candidates.
✕Probably not a fit
Patients with recurrent pterygium, a history of prior ocular surface surgery, active ocular infection, or severe ocular surface disease are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective single-arm interventional protocol enrolls adults with primary pterygium and performs conjunctival transpositional surgery by mobilizing and repositioning the native pterygium tissue. The technique preserves Tenon's layer, avoids creating a bare sclera, and does not use adjunctive therapies such as mitomycin C or grafting. Participants are followed after surgery to record recurrence rate and functional outcomes including ocular surface health and visual symptoms. Patients with recurrent pterygium, prior ocular surface surgery, active infection, or severe ocular surface disease are excluded.
Why it matters
Potential benefit: If successful, the technique could reduce pterygium recurrence while preserving conjunctival tissue and avoiding grafts or adjunctive drugs.
How similar studies have gone: Conjunctival-sparing approaches and conjunctival autografts have shown good results in lowering recurrence, but purely transpositional techniques without adjuncts are less widely studied and have limited published outcome data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years or older * Primary pterygium involving the cornea * Ability to provide informed consent Exclusion Criteria: * Recurrent pterygium * Previous ocular surface surgery * Active ocular infection or inflammation * Severe ocular surface disease
Where it's running
-
Alzahra Eye Hospital, Zahedan University of Medical Sciences
Zahedan, Sistan and Balochistan, Iran Recruiting
Study contacts
- Study coordinator: Mohammed Arish, MD, FRCS
- Email: mohammad.erish@zaums.ac.ir
- Phone: 09151419155
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing cauterization and fibrin glue for eye surgery in pterygium treatment
This study tests whether using cauterization or fibrin glue during eye surgery helps prevent pterygium from coming back in patients who need the growth removed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.